BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 37217351)

  • 1. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis.
    Lin EK; Hsieh MC; Chen CH; Lu YJ; Wu SY
    Medicine (Baltimore); 2016 Dec; 95(52):e5522. PubMed ID: 28033247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC.
    Simkens GA; van Oudheusden TR; Nieboer D; Steyerberg EW; Rutten HJ; Luyer MD; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2016 Dec; 23(13):4214-4221. PubMed ID: 27027308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
    Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280
    [No Abstract]   [Full Text] [Related]  

  • 7. [Analysis of perioperative efficacy and safety of cytoreductive surgery in the treatment of colorectal cancer peritoneal metastases].
    Chen WW; Wang H; Li Y; Yuan ZX; Liu D; Wu ZJ; Deng WH; Luo R; Chen J; Cai J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):513-521. PubMed ID: 35754216
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes.
    Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S
    Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: a 13 years-retrospective monocentric study.
    Livin M; Leonard D; Bachmann R; Remue C; Barbois S; Cotte E; Van Den Eynde M; De Cuyper A; Sinapi I; Van Maanen A; Kartheuser A
    Acta Gastroenterol Belg; 2022; 85(4):573-579. PubMed ID: 36566366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the immuno-peritoneal cancer index in peritoneal metastatic patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Yildirim Y; Sokmen S; Cevlik AD; Bisgin T; Manoglu B; Obuz F
    Langenbecks Arch Surg; 2023 May; 408(1):182. PubMed ID: 37148400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
    Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: a collaborative observational study from Korea and Japan.
    Kitaguchi D; Park EJ; Baik SH; Sasaki S; Tsukada Y; Ito M
    Int J Surg; 2024 Jan; 110(1):45-52. PubMed ID: 37800569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
    Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
    JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry.
    Kelly ME; O'Sullivan NJ; Bolger JC; Polignano F; Youssef H; Renehan A; Malcomson L; Alves S; Cecil T; Mulsow J; Moran B; Mohamed F;
    Br J Cancer; 2023 Jan; 128(1):42-47. PubMed ID: 36347966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
    Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M
    World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.
    Bhullar D; O'Dwyer S; Wilson M; Saunders MP; Kochhar R; Barriuso J; Aziz O
    Ann Surg Oncol; 2023 Feb; 30(2):792-801. PubMed ID: 36400886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actual 5-Year Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis of Colorectal Origin.
    Sarfaty E; Khajoueinejad N; Yu AT; Hiotis S; Golas BJ; Sarpel U; Labow DM; Cohen NA
    Ann Surg Oncol; 2024 Mar; 31(3):1970-1979. PubMed ID: 37989953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.